SEC Form 3 · accession 0001354488-15-004802

Acer Therapeutics Inc. · ACER

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Scientific Officer

Period of report

Oct 26, 2015

Accepted (ET)

Nov 3, 2015 · 5:15 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001069308

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	holding	—	—		—	4,045	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F1	$72.04	holding	—	—	—	—	Apr 30, 2020	Common Stock	937	—	D
Employee Stock Option (right to buy)^F1	$49.95	holding	—	—	—	—	Jan 4, 2021	Common Stock	937	—	D
Employee Stock Option (right to buy)^F2	$30.40	holding	—	—	—	—	Jan 6, 2022	Common Stock	1,308	—	D
Employee Stock Option (right to buy)^F2	$30.40	holding	—	—	—	—	Jan 6, 2022	Common Stock	2,617	—	D
Employee Stock Option (right to buy)^F1	$30.40	holding	—	—	—	—	Jan 6, 2022	Common Stock	1,199	—	D
Employee Stock Option (right to buy)^F1	$14.00	holding	—	—	—	—	Apr 29, 2023	Common Stock	2,500	—	D
Employee Stock Option (right to buy)^F3	$14.56	holding	—	—	—	—	Feb 28, 2024	Common Stock	8,078	—	D
Employee Stock Option (right to buy)^F3	$6.56	holding	—	—	—	—	Mar 2, 2025	Common Stock	7,500	—	D

F1The option vests quarterly on the anniversary of the date of grant over a period of three years.
F2The performance-based options began vesting quarterly over a three year-period upon achievement of certain key milestone events. On September 12, 2012, the first tranche of one-third of the performance option shares commenced three-year quarterly vesting upon achievement of the first key milestone, which was Opexa Therapeutics, Inc. (the "Company") initiating a clinical trial for its product candidate Tcelna in Secondary Progressive Multiple Sclerosis. On February 5, 2013, the second tranche of two-thirds of the performance option shares commenced three-year quarterly vesting upon achievement of the second key milestone, which was the Company entering into a collaboration, partnership or other strategic arrangement involving rights in the United States for Tcelna.
F325% of the shares vest on the one-year anniversary of the grant date, and the remaining 75% vest quarterly over the remaining three years.

Exhibit List: Exhibit 24 - Power of Attorney